**The Correlation of FGF23 Level with Parathyroid Hormone Level at Different Stage of Chronic Kidney Disease**

***Simah ALNUAIMI1, , Hakan ÇOLAK2, Abdullah RAOOF3***

***1****Scince Inistitution, Chemstery Department, Çankırı Karatekin University, Çanıkrı, Turkey*

***2****Scince Inistitution, Chemstery Department, Çankırı Karatekin University, Çanıkrı, Turkey*

***3****Medicine Faculty, Kırkuk University*

|  |
| --- |
| **Abstract**  The aim of current study was determining the levels of FGF-23 in patients at different stage of hronic kidney disease, and found the correlation between FGF23 level and some electrolytes and PTH hormone. The current study is a case (patient chronic renal failure) - control (healthy persons) study Chronic renal disease patients of both genders (65 males and 44 females) aged 20 to 71 years’ old who visit Azadi Teaching Hospital and Al-jumhuri Hospital in Kirkuk, Iraq (from October to December 2020), are the target population. Per patient with end-stage renal disease received hemodialysis twice or three times a week for a total of four hours. The results of the current study demonstrated that the highest age group with renal failure was 51-60 years, where it was 26.2%. Then, the age group was 61-70, as it was 22.1%, while the lowest age group of patients of renal failure was 31-40, where it was 5.4%. The results of the current study showed that the percentage of healthy people in the current study was 40 (26.8%), while the number of patients with kidney failure was 83 (55.7%), while other stages of kidney disease were reported, the third stage included 9 (6%) patients while. The fourth stage included 17 (11.4%) patients. Calcium levels in CDK (male and female) patients showed significant (P≤0.05) decrease compare with control group. Phosphorus, FGF-23 and PTH levels in CDK (male and female) patients were showed significant (P≤0.05) increase compare with control group. |
| Keywords: Fibroblast growth factor 23, Chronic kidney disease, Hyperphosphatemia. |

**References**

1. Assadi, F. 2013. Strategies to reduce the incidence of chronic kidney disease in children: time for action. Journal of nephrology, 26(1), 41-47.
2. Ben-Dov, I.Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R., Kuro-o, M., Mohammadi, M., Sirkis, R., Naveh-Many, T. and Silver, J. 2007. The parathyroid is a target organ for FGF23 in rats. The Journal of clinical investigation, 117(12), 4003-4008
3. Benghanem Gharbi, M.B., Elseviers, M., Zamd, M., Alaoui, A.B., Benahadi, N., Trabelssi, E.H., Bayahia, R., Ramdani, B. and De Broe, M.E., 2016. Chronic kidney disease, hypertension, diabetes, and obesity in the adult population of Morocco: how to avoid ―over‖-and ―under‖-diagnosis of CKD. Kidney international, 89(6), 1363-1371.
4. Curthoys, N. P., and Moe, O. W. 2014. Proximal tubule function and response to acidosis. Clinical journal of the American Society of Nephrology, 9(9), 1627- 1638.
5. De Groot, T., Lee, K., Langeslag, M., Xi, Q., Jalink, K., Bindels, R. J., and Hoenderop, J. G. 2009. Parathyroid hormone activates TRPV5 via PKA-dependent phosphorylation. Journal of the American Society of Nephrology, 20(8), 1693-1704.
6. Evans, P. D., and Taal, M. W. 2015. Epidemiology and causes of chronic kidney disease. Medicine, 43(8), 450-453.
7. Farrow, E.G., Davis, S.I., Summers, L.J. and White, K.E. 2009. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. Journal of the American Society of Nephrology, 20(5), 955-960.